Exploring Protein Analysis: Techniques and Applications in Bioanalysis
The foundation of bioanalytical research lies in the analysis of proteins, offering intricate insights of life at the molecular level. By deconstructing the aspects of protein structures, functions, and expressions, we unlock invaluable insights of disease mechanisms, drug responses, and cellular processes.
Aliri’s expertise in mass spectrometry generates precise data, guiding us toward pivotal discoveries in diagnostics, therapies, and individualized treatments. View our on-demand webinar where industry experts Shane Karnik, Senior Laboratory Director, Edward Brewer, Senior Director of R&D, and Matthew Hartle, Analytical Chemist, cover:
- The current state of the industry and how Aliri is adapting digital tools to explore proteins.
- Various approaches to streamline workflows related to protein analysis.
- Methodologies that aid in differentiating protein species.
- Guidance for Regulatory GLP and human-clinical support.
- Future trends and emerging techniques in the protein analysis space.
A bioanalytical discovery strategy for fast and flexible decision making
When navigating drug discovery, it is critical to strategically balance project timelines and investments, and to select a reliable bioanalysis partner who is fully dedicated to the success of your program. Our ability to provide technical expertise and quick turnarounds will enable you to select your drug candidate and move on to the next phase of your project with ease and efficiency.
View our on-demand webinar where industry experts Edward Brewer, Senior Director of R&D, Mass Spectrometry and Systems Validation, and Ryan Adler, Manager of Laboratory Operations, cover:
- Advancements in Bioanalysis and strategic techniques used to quantify drug compounds during the discovery process.
- How our streamlined workflows enable fast and flexible decision-making and keep lead times down to 6-8 weeks.
- Navigating challenges faced during the discovery phase and exploring strategies to overcome these potential obstacles.
- How we advance molecules with ease and precision from Discovery to GLP.
LC/MS/MS VS. LC/HRMS: Identifying and quantifying oligonucleotides
LC/MS/MS and LC/HRMS are formidable instruments employed in mass spectrometry for the identification and quantification of Oligonucleotides (OGNTs). Utilizing these approaches, drug developers can obtain detailed insights into the composition and structure of molecules for biotechnology and pharmaceuticals.
Considerations for choosing the right approach for your drug development project will depend on:
- What instrument you have
- Where you want to go
- How much information you want to collect in a single injection
Discover which technique is best for you.
Optimizing small molecule drug development strategies: A step by step approach to a rugged method
Creating a rugged method for the development of small molecule drugs is crucial in the quest for successful therapies. A systematic approach not only guarantees data consistency and reliability but also empowers you to make well-informed decisions, ultimately boosting project efficiency and success.
To help you navigate the complexities and uncertainties that come with advancing small molecules for drug development, we’ve outlined a robust strategy that includes 7 crucial steps.
Download our fact sheet to learn more.
Oligonucleotides: A Bioanalytical CRO’s Perspective on Current and Future State
Since the first oligonucleotide (OGNT) drug was approved by the FDA for clinical use in 1998, the industry has made significant progress in the advancement of techniques, technology, and development methods. However, due to the complexity and sensitivity of OGNTs, there are still challenges to navigate and overcome within drug development and bioanalytical analysis.
Join oligonucleotide bioanalysis SME Troy Voelker, Director of Laboratory Operations at Aliri, as he discusses:
- Current and future state of the bioanalysis of OGNTs
- Common approaches to bioanalysis of OGNTs
- Evaluating and selecting the optimal and strategic approach
A Comprehensive Guide to Optimizing Your Small Molecule Drug Development Strategy
Given that small molecules make up more than 50% of the drug development pipeline, adopting a proactive non-clinical to clinical strategy is crucial for accelerating your program.
A holistic bioanalysis strategy that incorporates spatial analysis allows researchers to produce quality data, identify drug targets, evaluate efficacy, and optimize delivery. Join industry experts Troy Voelker and Corinne Ramos as they cover a step-by-step approach to a rugged method, including:
- Strategies moving from pre-clinical to clinical
- Spatial bioanalysis and moving into GLP
- Molecule stability and reproducibility
- Handling matrices and compounds
- Different instrumentation and uses
- Cold storage check list
- Ongoing use of ICH M-10
View our on-demand webinar to learn how to implement a comprehensive strategy that expedites the development of your small molecule.
Investigation of immune-checkpoints for personalized therapy selection
Monoclonal antibody-based therapy targeting PD1 blockage has brought a transformative shift in the immunotherapeutic strategy against solid tumors. However, the limited effectiveness of this treatment stems from the absence of precise methodologies, such as immunohistochemistry, for identifying patients who could potentially respond well to immune checkpoint inhibitor therapy.
Because a single biomarker is not accurate enough to predict the interaction of the drug at the site of action, we developed a strategy to investigate the complexity of the tumor microenvironment, while also guiding patients towards combination therapy. Using multiplexed high throughput analysis, we have been able to investigate pathways of immune modulation at the molecular level to drug response and resistance.
Download our application note to learn more:
Sequential pathogenic events in Type I Diabetes
Type 1 diabetes (T1D) arises due to the autoimmune degradation of insulin producing β cells. In order to cure or halt this disease, understanding how cell types, cell states, and cell-cell interactions evolve during T1D development is essential.
Utilizing our proprietary imaging analysis tools, we were able to segment cells to identify cell populations for spatial analysis and further classification in diabetes with precision. Our deep data analysis workflows and advanced imagine techniques introduce new opportunities to investigate the pathology of T1D within the pancreas.
Download our application note to learn more:
Spatially-resolved tumor gene expression analysis
As cancer advances, tumor cells come into contact with new cell types within the microenvironment, but it is still unclear how the tumor cells adapt to new environments. Spatial transcriptomics is a powerful approach to uncover mechanisms that allow tumors to invade the microenvironment and help discover biomarkers for potential therapeutic targets.
In this application note, we outline how we fine-tuned and merged spatial transcriptomics with laser microdissection (LMD) to identify distinct patterns in genes in tumor cells throughout the stages of cancer progression.
Download our application note to learn more:
Intra-tumoral metabolic plasticity
Just as genetic diversity varies, the metabolic characteristics of cancer exhibit significant heterogeneity due to varied signals within the tumor microenvironment. Hence, addressing metabolic adaptability is crucial when developing cancer immunotherapy strategies.
Utilizing our proprietary Mass Spectrometry Imaging and GeoMx platforms, we were able to evaluate the interactions between metabolic pathways and functions of immune cells to assist in the development of new cancer metabolism drugs. A combined workflow of Quantitative Mass Spectrometry Imaging (QMSI) and GeoMx allows for a better understanding of both direct and indirect modulation of anti-tumor immunity through a better understanding of the tumor immune cell interface.
Download our application note to learn more: